Related Experiment Video
Updated: Jul 4, 2026

Training Persons with Spinal Cord Injury to Ambulate Using a Powered Exoskeleton
Published on: June 16, 2016
Secondary osteoporosis in long-term bedridden patients with cerebral palsy
Toshiyuki Iwasaki1, Kenji Takei, Shinya Nakamura
1Department of Pediatrics, Kitasato University School of Medicine, Kanagawa, Japan. tiwasaki@kitasato-u.ac.jp
Insights
Risedronate therapy, combined with vitamin D, significantly improves bone mineral density in pediatric patients with cerebral palsy and secondary osteoporosis. Early aggressive treatment is recommended for optimal outcomes.
Area of Science:
- Pediatric Endocrinology
- Bone Metabolism
- Neuromuscular Disorders
Background:
- Cerebral palsy (CP) frequently leads to secondary osteoporosis in children.
- Effective treatment strategies for pediatric secondary osteoporosis are crucial.
Purpose of the Study:
- To investigate the efficacy of vitamin D (alfacalcidol) and bisphosphonate (risedronate) therapies in pediatric patients with CP and secondary osteoporosis.
- To evaluate treatment influence on bone mineral density (BMD) and bone turnover markers.
Main Methods:
- A 6-month study involving 20 pediatric patients (age 1-16 years) with CP and secondary osteoporosis.
- Patients were divided into two groups: vitamin D monotherapy or vitamin D with risedronate.
- Bone mineral density (BMD) and bone turnover markers (BAP, NTX/Cr) were measured pre- and post-treatment.
Main Results:
- Combination therapy with alfacalcidol and risedronate was more effective in improving BMD than alfacalcidol monotherapy.
- Bone turnover markers (BAP and NTX/Cr) generally decreased post-treatment, but correlations with BMD changes were not significant.
- Treatment efficacy was independent of patient age, sex, medication regimen, or enteral nutrition.
Conclusions:
- Risedronate therapy is effective for secondary osteoporosis in children with cerebral palsy.
- Aggressive early treatment with risedronate is recommended as its efficacy is not influenced by patient-specific factors.
Background:
The aim of the present paper was to investigate 20 pediatric patients with cerebral palsy and secondary osteoporosis and consider the efficacy, influence and index of treatment.
Methods:
A total of 10 boys and 10 girls, age 1-16 years (mean 7.6 years) with secondary osteoporosis and cerebral palsy treated for 6 months, were studied. Bone mineral density (BMD) was measured. The bone turnover markers were measured just before and 4 months after treatment or at the time of early discontinuation of treatment. The treatment was classified into two groups: vitamin D (alfacarcidol) only; and with bisphosphonate (risedronate).
Results:
Monotherapy with alfacarcidol was effective for secondary osteoporosis in children, but when used in combination with risedronate it was even more effective in improving BMD. In the two groups, bone-specific alkaline phosphate (BAP) decreased from pretreatment to post-treatment assessment in all but one case, but there was no significant correlation in the difference in DeltaBAP with DeltaBMD. DeltaBAP assumed changes in BAP in treatment either before or after, and DeltaBMD also assumed changes in BMD. N-telopeptides of type I collagen (NTX)/Cr decreased in all cases. The correlation of DeltaNTX/Cr with DeltaBMD was not significant. The therapy and its efficacy did not correlate to the patients' age, sex, medicine regimen or enteral nutrition.
Conclusions:
Risedronate therapy is effective for patients presenting with secondary osteoporosis with cerebral palsy. Moreover, it is desirable to treat patients more aggressively from the early stage because risedronate is not affected by the patients' other factors.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Secondary Spinal Cord Injury llI: Pathophysiology
Bone Remodeling
Spinal Cord Injury ll: Pathophysiology
